Skip to main content
. 2017 May 18;12(6):947–954. doi: 10.2215/CJN.11631116

Figure 3.

Figure 3.

Estimates of arteriovenous fistula (AVF) cost-effectiveness decrease as life-expectancy decreases. Estimated costs and quality-adjusted life-months (QALMs) for AVF placement, arteriovenous graft (AVG) placement, and continued central venous catheter (CVC) use for the 75- to 79-year-old age group are depicted by three life expectancy categories: (A) highest, (B) intermediate, and (C) lowest quartiles. The AVF option costs were higher with lower life expectancy.